Dorsavi Ltd. · ASX:DVL

Dorsavi — Investor Presentation (September 2016)

28 slides from Dorsavi's investor presentation, Sep 12, 2016

  1. Slide 1: Inspiring the World to Move Well

    For personal use only // 1 INSPIRING THE WORLD TO MOVE WELL © Copyright dorsaVi Ltd 2016

  2. Slide 2: We Measure Quality of Movement in OHS, Clinical and Elite Sports Environments

    // 2 WE MEASURE QUALITY OF MOVEMENT IN OHS, CLINICAL AND ELITE SPORTS ENVIRONMENTS For personal use only • dorsaVi Ltd (ASX: DVL) listed in Dec 2013 • Multiple patents involving movement analysis • FDA Clearance, CE Mark (EU) and TGA (Aust) • Cleared and selling in US, Europe and Australia • Strong

  3. Slide 3: Compelling Investment Case

    // 3 COMPELLING INVESTMENT CASE • Attractive revenue model with fast ramp up For personal use only • 3 key business divisions with diversified revenue streams and exposure to fast growing markets • Market leader with first mover advantage • Improving financial performance as cost base begins to be l

  4. Slide 4: dorsaVi's Core Expertise

    dorsaVi’s CORE EXPERTISE // 4 Wearable sensors – gather For personal use only accurate movement & muscle activity data Reports – automated report generation to multiple levels (Clinician, Patient, Workplace & Athlete) Cloud comms – storage, dissemination of data, syncing, updates, big data pooling &

  5. Slide 5: Major Achievements Over the Past Months

    // 5 MAJOR ACHIEVEMENTS OVER THE PAST 12 MONTHS ViSafe (OHS) For personal use only • Launched OHS product into the UK and the US • New contracts with major OHS clients in UK & US (Toyota, Jaguar, TFL, Heathrow) • Repeat & large scale OHS deals contracts (TFL, Crown and Monash/Allianz) • Developed an

  6. Slide 6: Financial Overview

    // 6 FINANCIAL OVERVIEW dorsaVi Ltd (ASX : DVL) For personal use only Share price $0.42 Shares on issue 149,914,616 Market capitalisation $63M 2013 2014 2015 2016 Revenue** 398,607 529,380 1,358,218 3,019,000 EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) Loss from continuing (1,659,235) (3,

  7. Slide 7: Changing Occupational Health & Safety Forever

    // 7 CHANGING OCCUPATIONAL HEALTH & SAFETY FOREVER For personal use only • Work injuries cost $250B p.a. (US) • Large untapped market with appetite for wearable data • Unique IP leading to reduced injuries & costs • Interventions involving: • Job assessment • Equipment change • Pre-employment screen

  8. Slide 8: Assessment and Metrics to Understand Movement Risk

    // 8 ASSESSMENT AND METRICS TO UNDERSTAND MOVEMENT RISK For personal use only © Copyright dorsaVi Ltd 2016

  9. Slide 9: Making a Huge Commercial Difference to Our Clients

    // 9 MAKING A HUGE COMMERICAL DIFFERENCE TO OUR CLIENTS Prior to dorsaVi Intervention • Case study from large organisation For personal use only 40 • Used dorsaVi sensors to identify risk & plan changes Number of injuries 35 30 • Third party provided pre-employment screening with ViMove 30 • Consuma

  10. Slide 10: Example of App to Be Used in the Field

    // 10 EXAMPLE OF APP TO BE USED IN THE FIELD For personal use only © Copyright dorsaVi Ltd 2016

  11. Slide 11: dorsaVi's OHS Platform & Annuity Revenue

    dorsaVi’S OHS PLATFORM & ANNUITY REVENUE // 11 Problem for major corporates: For personal use only • Lack of visibility on injuries and costs • Poor ability to understand and change issues dorsaVi offering: • ViSafe projects (real data from the field) • Provides insights, risk matrix and solutions •

  12. Slide 12: Massive Market Looking for Cost Saving

    // 12 MASSIVE MARKET LOOKING FOR COST SAVING For personal use only Health IT and electronic health applications are reshaping the health care workforce and reducing $560B burden on health systems globally by: • Improving decision making & timely intervention • Allowing point-of-care diagnosis and tr

  13. Slide 13: Clinical Evidence Shows Dramatic Change in Back Pain

    // 13 CLINICAL EVIDENCE SHOWS DRAMATIC CHANGE IN BACK PAIN $800,000 Long term disabled For personal use only dorsaVi Impact Opioids dependence $700,000 Spinal Cord $600,000 Stimulation, Opioids $500,000 Repeat Spinal Surgery, Opioids $400,000 $300,000 Surgery, Fusion, Opioids $200,000 Referral to MR

  14. Slide 14: Compelling Applications for the Clinical Market

    // 14 COMPELLING APPLICATIONS FOR THE CLINICAL MARKET For personal use only Live Assessment Live Training (Treatment) Monitoring Tailored Biofeedback FDA Cleared Movement re-education Data capture from the Programmed alerts and with live data feedback patient’s real world reminders to guide (8-24 ho

  15. Slide 15: Clinical Platform to Manage Data, Reports and Communication

    // 15 CLINICAL PLATFORM TO MANAGE DATA, REPORTS AND COMMUNICATION For personal use only © Copyright dorsaVi Ltd 2016

  16. Slide 16: Multiple Applications Across the Continuum of Care

    // 16 MULTIPLE APPLICATIONS ACROSS THE CONTINUUM OF CARE For personal use only • Clinical applications for majority of conditions treated in physio practices • Modular business model creating annuity revenue and assisting scale in the US clinical market • Building new passive revenue streams for tim

  17. Slide 17: High Profile Sports Market Wanting New Insights

    // 17 HIGH PROFILE SPORTS MARKET WANTING NEW INSIGHTS For personal use only © Copyright dorsaVi Ltd 2016

  18. Slide 18: Providing Unique Insights in Elite Sports

    // 18 13 PROVIDING UNIQUE INSIGHTS IN ELITE SPORTS For personal use only Previous Management of Stress Fractures Step 1 Step 2 Step 3 Step 4 Bone Scan X-Ray MRI Surgery Games missed = 12-24 weeks (30 – 60 games) © Copyright dorsaVi Ltd 2016

  19. Slide 19: Changing the Sports Prevention Paradigm

    // 19 CHANGING THE SPORTS PREVENTION PARADIGM For personal use only New Management of Stress Fractures Step 1 Step 2 Step 3 dorsaVi assessment Bone Scan 3-4 weeks Rehab Games missed = 3 weeks (6-9 games) 3 weeks out instead of 12-24 weeks © Copyright dorsaVi Ltd 2016

  20. Slide 20: For personal use only

    For personal use only // 20 ? © Copyright dorsaVi Ltd 2016

  21. Slide 21: dorsaVi Technology Being Used by World Leaders in >65 Projects

    // 21 dorsaVi TECHNOLOGY BEING USED BY WORLD LEADERS IN >65 PROJECTS For personal use only © Copyright dorsaVi Ltd 2016

  22. Slide 22: Market Is Ready - Exploiting the Current Market

    // 22 MARKET IS READY - EXPLOTING THE CURRENT MARKET For personal use only © Copyright dorsaVi Ltd 2016

  23. Slide 23: Product Evolution to Maintain 1st Market Mover Advantage

    // 23 PRODUCT EVOLUTION TO MAINTAIN 1ST MARKET MOVER ADVANTAGE For personal use only Cross platform (Android, iPhone) Quick pairing of sensors (10s vs. 90s) - better usability 72 hours monitoring (stand alone) Smaller and lighter sensors Higher data rates Lower COGS for sensor kits Lower COGS for EM

  24. Slide 24: Collaborative Development for US Partners in Clinical Market

    // 24 COLLABORATIVE DEVELOPMENT FOR US PARTNERS IN CLINICAL MARKET For personal use only • Select Medical – large outpatient and PT group (2,000 clinical sites) • Business model with athletic screening of school/college aged students – initial deal across 20 sites • Previously used a manual video ba

  25. Slide 25: Significant Untapped Opportunity

    // 25 SIGNIFICANT UNTAPPED OPPORTUNITY For personal use only 150 devices in 10 devices  80 devices the market in past 12 months 24,000 Physios (0.5% penetration) 70 devices in the market 48,000 Physios 80 devices in the market 284,000 physical therapists • Immediate target market: > 350,000 Physios

  26. Slide 26: Upcoming Newsflow

    // 26 UPCOMING NEWSFLOW For personal use only • Long term OHS contracts with major corporates (US, UK & Aust) • Repeat deals with major insurers • Recruit first patient into US low back registry • Publication of Health Economic evaluation from large clinical trial • Launch App based mini sensor into

  27. Slide 27: dorsaVi Contact Details

    // 27 dorsaVi™ For personal use only Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 Office: +61 9652 2192 | Mobile: +61 417 882 267 ar@dorsaVi.com | dorsaVi.com © Copyright dorsaVi Ltd 2016

  28. Slide 28: Board and Senior Management

    BOARD AND SENIOR MANAGEMENT For personal use only Chairman Non Executive Director Non Executive Director Non Executive Director Herb Elliott Greg Tweedly Michael Panaccio Ash Attia Director & CEO Andrew Ronchi CFO CIO CPO CMO Head of Sales and Head of Sales and Head of Sales and Damian Connellan Mea

dorsaVi — Investor Presentation (September 2016) on 6ix